Loading
Life sciences · Journal article
Translational Psychiatry · October 25, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Obesity and major depressive disorder (MDD) frequently co-occur and confer mutually reinforcing risks, including elevated suicidality. Tirzepatide has demonstrated substantial metabolic benefits, yet its psychiatric safety in high-risk populations with MDD remains uncertain. This study aimed to compare suicidal ideation outcomes among adults with comorbid obesity and MDD initiating tirzepatide versus non–GLP-1RA anti-obesity medications. This retrospective, propensity score–matched cohort study used deidentified electronic health record data from the TriNetX Global Collaborative Network. Adults (≥18 years) with diagnosed obesity and MDD who initiated tirzepatide or non–GLP-1RA anti-obesity medications were included. The primary outcome was suicidal ideation. Secondary outcomes included anxiety disorders, insomnia disorders, all-cause mortality, and emergency department or inpatient encounters. Among 24,103 matched pairs, tirzepatide use was associated with lower risk of suicidal ideation (HR, 0.63; 95% CI, 0.42–0.93), anxiety disorders (HR, 0.83; 95% CI, 0.81–0.86), insomnia disorders (HR, 0.92; 95% CI, 0.86–0.98), all-cause mortality (HR, 0.38; 95% CI, 0.25–0.58), and emergency department visits or hospitalizations (HR, 0.94; 95% CI, 0.89–0.99). Risk reduction was generally consistent across prespecified subgroups. Control outcome analyses supported the internal validity of the findings. In conclusion, this study provides real-world evidence that tirzepatide initiation was associated with a lower recorded risk of suicidal ideation, as well as reduced anxiety, insomnia, all-cause mortality, emergency department visits, and hospitalizations, among adults with comorbid obesity and MDD. This observational association should not be interpreted as evidence of a direct antisuicidal effect. These findings support the potential for tirzepatide to serve as a metabolically favorable treatment option associated with a lower risk of suicidal ideation in this vulnerable, high-risk population.